352 related articles for article (PubMed ID: 8387391)
21. Distinct mdm2/p53 expression patterns in liposarcoma subgroups: implications for different pathogenetic mechanisms.
Pilotti S; Della Torre G; Lavarino C; Di Palma S; Sozzi G; Minoletti F; Rao S; Pasquini G; Azzarelli A; Rilke F; Pierotti MA
J Pathol; 1997 Jan; 181(1):14-24. PubMed ID: 9071998
[TBL] [Abstract][Full Text] [Related]
22. Molecular and immunohistochemical p53 status in liposarcoma and malignant fibrous histiocytoma: identification of seven new mutations for soft tissue sarcomas.
Taubert H; Würl P; Meye A; Berger D; Thamm B; Neumann K; Hinze R; Schmidt H; Rath FW
Cancer; 1995 Oct; 76(7):1187-96. PubMed ID: 8630896
[TBL] [Abstract][Full Text] [Related]
23. Molecular and immunohistochemical identification of p53 alterations in bone and soft tissue sarcomas.
Mousses S; McAuley L; Bell RS; Kandel R; Andrulis IL
Mod Pathol; 1996 Jan; 9(1):1-6. PubMed ID: 8821948
[TBL] [Abstract][Full Text] [Related]
24. MDM2 amplification and loss of heterozygosity at Rb and p53 genes: no simultaneous alterations in the oncogenesis of liposarcomas.
Schneider-Stock R; Walter H; Radig K; Rys J; Bosse A; Kuhnen C; Hoang-Vu C; Roessner A
J Cancer Res Clin Oncol; 1998; 124(10):532-40. PubMed ID: 9829856
[TBL] [Abstract][Full Text] [Related]
25. Amplification of a gene encoding a p53-associated protein in human sarcomas.
Oliner JD; Kinzler KW; Meltzer PS; George DL; Vogelstein B
Nature; 1992 Jul; 358(6381):80-3. PubMed ID: 1614537
[TBL] [Abstract][Full Text] [Related]
26. Distinct MDM2 and P14ARF expression and centrosome amplification in well-differentiated liposarcomas.
Perucca-Lostanlen D; Rostagno P; Grosgeorge J; Marcié S; Gaudray P; Turc-Carel C
Genes Chromosomes Cancer; 2004 Feb; 39(2):99-109. PubMed ID: 14695989
[TBL] [Abstract][Full Text] [Related]
27. Lack of MDM2 amplification in human leukaemia.
Ridge SA; Dyer M; Greaves MF; Wiedemann LM
Br J Haematol; 1994 Feb; 86(2):407-9. PubMed ID: 8199038
[TBL] [Abstract][Full Text] [Related]
28. Most malignant fibrous histiocytomas developed in the retroperitoneum are dedifferentiated liposarcomas: a review of 25 cases initially diagnosed as malignant fibrous histiocytoma.
Coindre JM; Mariani O; Chibon F; Mairal A; De Saint Aubain Somerhausen N; Favre-Guillevin E; Bui NB; Stoeckle E; Hostein I; Aurias A
Mod Pathol; 2003 Mar; 16(3):256-62. PubMed ID: 12640106
[TBL] [Abstract][Full Text] [Related]
29. Loss of heterozygosity at 12q14-15 often occurs in stage I soft tissue sarcomas and is associated with MDM2 amplification in tumors at various stages.
Taubert H; Schuster K; Brinck U; Bartel F; Kappler M; Lautenschläger C; Bache M; Trump C; Schmidt H; Holzhausen HJ; Würl P; Schlott T
Mod Pathol; 2003 Nov; 16(11):1109-16. PubMed ID: 14614050
[TBL] [Abstract][Full Text] [Related]
30. Analysis of the molecular species generated by MDM2 gene amplification in liposarcomas.
Tamborini E; Della Torre G; Lavarino C; Azzarelli A; Carpinelli P; Pierotti MA; Pilotti S
Int J Cancer; 2001 Jun; 92(6):790-6. PubMed ID: 11351297
[TBL] [Abstract][Full Text] [Related]
31. Sporadic amplification of the c-fms proto-oncogene in human musculoskeletal sarcomas.
Castresana JS; Barrios C; Ruiz J; Gómez L; Kreicbergs A
Anticancer Res; 1993; 13(3):807-10. PubMed ID: 8317916
[TBL] [Abstract][Full Text] [Related]
32. p53 and MDM2 alterations in osteosarcomas: correlation with clinicopathologic features and proliferative rate.
Lonardo F; Ueda T; Huvos AG; Healey J; Ladanyi M
Cancer; 1997 Apr; 79(8):1541-7. PubMed ID: 9118036
[TBL] [Abstract][Full Text] [Related]
33. p53 expression and its relationship to DNA alterations in bone and soft tissue sarcomas.
Wadayama B; Toguchida J; Yamaguchi T; Sasaki MS; Yamamuro T
Br J Cancer; 1993 Dec; 68(6):1134-9. PubMed ID: 8260365
[TBL] [Abstract][Full Text] [Related]
34. Molecular abnormalities in liposarcoma: role of MDM2 and CDK4-containing amplicons at 12q13-22.
Pilotti S; Della Torre G; Lavarino C; Sozzi G; Minoletti F; Vergani B; Azzarelli A; Rilke F; Pierotti MA
J Pathol; 1998 Jun; 185(2):188-90. PubMed ID: 9713346
[TBL] [Abstract][Full Text] [Related]
35. Abnormalities of the p53 MDM2 and DCC genes in human leiomyosarcomas.
Patterson H; Gill S; Fisher C; Law MG; Jayatilake H; Fletcher CD; Thomas M; Grimer R; Gusterson BA; Cooper CS
Br J Cancer; 1994 Jun; 69(6):1052-8. PubMed ID: 8198970
[TBL] [Abstract][Full Text] [Related]
36. Characterization of the 12q13-15 amplicon in soft tissue tumors.
Nilbert M; Rydholm A; Mitelman F; Meltzer PS; Mandahl N
Cancer Genet Cytogenet; 1995 Aug; 83(1):32-6. PubMed ID: 7656201
[TBL] [Abstract][Full Text] [Related]
37. Mutation of the p53 gene in human soft tissue sarcomas: association with abnormalities of the RB1 gene.
Stratton MR; Moss S; Warren W; Patterson H; Clark J; Fisher C; Fletcher CD; Ball A; Thomas M; Gusterson BA
Oncogene; 1990 Sep; 5(9):1297-301. PubMed ID: 2216456
[TBL] [Abstract][Full Text] [Related]
38. SAS amplification in soft tissue sarcomas.
Smith SH; Weiss SW; Jankowski SA; Coccia MA; Meltzer PS
Cancer Res; 1992 Jul; 52(13):3746-9. PubMed ID: 1319830
[TBL] [Abstract][Full Text] [Related]
39. p53 and ras mutations in Ewing's sarcoma.
Radig K; Schneider-Stock R; Röse I; Mittler U; Oda Y; Roessner A
Pathol Res Pract; 1998; 194(3):157-62. PubMed ID: 9587933
[TBL] [Abstract][Full Text] [Related]
40. Alterations of the p53, Rb and MDM2 genes in osteosarcoma.
Miller CW; Aslo A; Won A; Tan M; Lampkin B; Koeffler HP
J Cancer Res Clin Oncol; 1996; 122(9):559-65. PubMed ID: 8781571
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
